European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture| Amgen
Amgen and UCB announced EU approval for EVENITY (romosozumab) to treat severe osteoporosis in postmenopausal women at high fracture risk. The therapy increases bone formation and reduces bone loss. First launches in the EEA are planned for H1 2020. EVENITY is now approved in 37 countries, including the U.S. and Japan.
How this was made
The 30-second read
Why it matters
The EU approval unlocks a market of millions of post‑menopausal women, expanding Amgen's revenue base.
Market read
Regulatory approval is a material catalyst for Amgen, likely prompting short‑term price appreciation.
What to watch
Potential cardiovascular safety concerns noted in trials may limit uptake.
Background
Amgen and UCB co‑developed EVENITY®, a bone‑forming monoclonal antibody for severe osteoporosis.
Ticker impact
European Commission granted marketing authorization for Amgen's EVENITY® (romosozumab) in the EU.
upward pressure as investors price in new EU market opportunity
Approval adds a major market for a high‑margin bone‑builder drug, expanding revenue potential.
Market effects
Strengthens the biotech/osteoporosis therapeutic segment and may boost peer valuations.
Adds a new product to the European pharma market, modestly supporting EU biotech indices.
Regulatory win for a large US biotech could influence global sentiment toward similar drug approvals.
Counterpoint
If post‑approval sales ramp slower than expected, the stock could face disappointment.
Key entities
- CompanyAmgen Inc.
US‑listed biotech firm developing EVENITY®.
- CompanyUCB
European pharma partner co‑developing the drug.
